Focus on aripiprazole - PubMed (original) (raw)

Review

Focus on aripiprazole

Ben Green. Curr Med Res Opin. 2004.

Abstract

This paper is an overview of recently published research concerning the neuroleptic drug aripiprazole. Aripiprazole is an antipsychotic drug with high affinity for D(2)- and D(3)-receptors and the dopamine autoreceptor. It also has serotonin 5-HT(1A)-receptor partial agonist and 5-HT(2A)-receptor antagonist properties. It is prescribed in the treatment of schizophrenia and is under the treatment of schizophrenia and schizoaffective investigation for treatment of bipolar disorder. The drug is given by mouth in an initial dose of 10 or 15 mg once daily. The dose may be adjusted at intervals of not less than 2 weeks up to a maximum of 30 mg daily. It appears to be useful in disorder and has a better side-effect profile than haloperidol.

PubMed Disclaimer

Similar articles

• [Aripiprazole use in children and adolescent psychiatric patients].
  Chevreuil C, Polard E, Lemonnier E, Guillemot P, Bentué-Ferrer D; Groupe d'Etude Interdisciplinaire de Bretagne << Psychotropes chez l'Enfant et l'Adolescent >>. Chevreuil C, et al. Therapie. 2011 Mar-Apr;66(2):123-30. doi: 10.2515/therapie/2011012. Epub 2011 Jun 6. Therapie. 2011. PMID: 21635859 Review. French.
• [Aripiprazole: a new atypical antipsychotic drug].
  Fischer B, Davids E, Gastpar M. Fischer B, et al. Fortschr Neurol Psychiatr. 2004 Sep;72(9):497-502. doi: 10.1055/s-2003-812530. Fortschr Neurol Psychiatr. 2004. PMID: 15365912 Review. German.
• Aripiprazole: an overview of a novel antipsychotic.
  Uzun S, Kozumplik O, Mimica N, Folnegović-Smalc V. Uzun S, et al. Psychiatr Danub. 2005 Jun;17(1-2):67-75. Psychiatr Danub. 2005. PMID: 16395846 Review.
• Aripiprazole: pharmacology, efficacy, safety and tolerability.
  Kinghorn WA, McEvoy JP. Kinghorn WA, et al. Expert Rev Neurother. 2005 May;5(3):297-307. doi: 10.1586/14737175.5.3.297. Expert Rev Neurother. 2005. PMID: 15938662 Review.
• Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors.
  Tadori Y, Forbes RA, McQuade RD, Kikuchi T. Tadori Y, et al. Eur J Pharmacol. 2009 Apr 1;607(1-3):35-40. doi: 10.1016/j.ejphar.2009.02.007. Epub 2009 Feb 13. Eur J Pharmacol. 2009. PMID: 19217900

Cited by

• In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain.
  Bortolozzi A, Díaz-Mataix L, Toth M, Celada P, Artigas F. Bortolozzi A, et al. Psychopharmacology (Berl). 2007 Apr;191(3):745-58. doi: 10.1007/s00213-007-0698-y. Epub 2007 Jan 30. Psychopharmacology (Berl). 2007. PMID: 17265076
• Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology.
  Davies MA, Sheffler DJ, Roth BL. Davies MA, et al. CNS Drug Rev. 2004 Winter;10(4):317-36. doi: 10.1111/j.1527-3458.2004.tb00030.x. CNS Drug Rev. 2004. PMID: 15592581 Free PMC article. Review.
• Efficacy and safety of aripiprazole in the treatment of bipolar disorder: a systematic review.
  Fountoulakis KN, Vieta E. Fountoulakis KN, et al. Ann Gen Psychiatry. 2009 Jul 27;8:16. doi: 10.1186/1744-859X-8-16. Ann Gen Psychiatry. 2009. PMID: 19635147 Free PMC article.
• Use of aripiprazole in clozapine induced enuresis: report of two cases.
  Lee MJ, Kim CE. Lee MJ, et al. J Korean Med Sci. 2010 Feb;25(2):333-5. doi: 10.3346/jkms.2010.25.2.333. Epub 2010 Jan 19. J Korean Med Sci. 2010. PMID: 20119596 Free PMC article.
• Aripiprazole in the treatment of depressive and anxiety disorders: a review of current evidence.
  Pae CU, Serretti A, Patkar AA, Masand PS. Pae CU, et al. CNS Drugs. 2008;22(5):367-88. doi: 10.2165/00023210-200822050-00002. CNS Drugs. 2008. PMID: 18399707 Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information